Spruce Biosciences, Inc.

NasdaqCM:SPRB Stock Report

Market Cap: US$20.3m

Spruce Biosciences Past Earnings Performance

Past criteria checks 0/6

Spruce Biosciences's earnings have been declining at an average annual rate of -17.1%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 85.2% per year.

Key information

-17.1%

Earnings growth rate

68.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate85.2%
Return on equity-76.4%
Net Margin-555.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Insufficient Growth At Spruce Biosciences, Inc. (NASDAQ:SPRB) Hampers Share Price

May 29
Insufficient Growth At Spruce Biosciences, Inc. (NASDAQ:SPRB) Hampers Share Price

Is Spruce Biosciences, Inc. (NASDAQ:SPRB) Popular Amongst Institutions?

Jan 12
Is Spruce Biosciences, Inc. (NASDAQ:SPRB) Popular Amongst Institutions?

Spruce Biosciences outlines milestones for 2021

Jan 06

Revenue & Expenses Breakdown

How Spruce Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:SPRB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247-3914-13
30 Jun 2410-43140
31 Mar 2410-47140
31 Dec 2310-48130
30 Sep 237-491335
30 Jun 234-48120
31 Mar 232-47120
31 Dec 220-46120
30 Sep 220-44126
30 Jun 220-441215
31 Mar 220-441124
31 Dec 210-421131
30 Sep 210-411130
30 Jun 210-401029
31 Mar 210-34826
31 Dec 200-30624
30 Sep 200-24321
30 Jun 200-17215
31 Mar 200-15212
31 Dec 190-13211

Quality Earnings: SPRB is currently unprofitable.

Growing Profit Margin: SPRB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SPRB is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.

Accelerating Growth: Unable to compare SPRB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPRB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: SPRB has a negative Return on Equity (-76.35%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies